These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 25848336)

  • 1. Targeted therapy in her2-positive metastatic breast cancer: a review of the literature.
    Zhu X; Verma S
    Curr Oncol; 2015 Mar; 22(Suppl 1):S19-28. PubMed ID: 25848336
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting HER2 in Advanced Breast Cancer.
    Zhu X; Joy AA
    Methods Mol Biol; 2017; 1652():63-77. PubMed ID: 28791634
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pertuzumab : evolving therapeutic strategies in the management of HER2-overexpressing breast cancer.
    O'Sullivan CC; Swain SM
    Expert Opin Biol Ther; 2013 May; 13(5):779-90. PubMed ID: 23530718
    [TBL] [Abstract][Full Text] [Related]  

  • 4. First-line therapy in HER2 positive metastatic breast cancer: is the mosaic fully completed or are we missing additional pieces?
    Fabi A; Malaguti P; Vari S; Cognetti F
    J Exp Clin Cancer Res; 2016 Jun; 35():104. PubMed ID: 27357210
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of pertuzumab for the treatment of HER2-positive metastatic breast cancer.
    De Mattos-Arruda L; Cortes J
    Adv Ther; 2013 Jul; 30(7):645-58. PubMed ID: 23881722
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Trastuzumab emtansine in human epidermal growth factor receptor 2-positive breast cancer: a review.
    Mathew J; Perez EA
    Curr Opin Oncol; 2011 Nov; 23(6):594-600. PubMed ID: 21986845
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Afatinib in the treatment of breast cancer.
    Hurvitz SA; Shatsky R; Harbeck N
    Expert Opin Investig Drugs; 2014 Jul; 23(7):1039-47. PubMed ID: 24870559
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Progression and treatment of HER2-positive breast cancer.
    Davoli A; Hocevar BA; Brown TL
    Cancer Chemother Pharmacol; 2010 Mar; 65(4):611-23. PubMed ID: 20087739
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Blockade of the HER family of receptors in the treatment of HER2-positive metastatic breast cancer.
    Sachdev JC; Jahanzeb M
    Clin Breast Cancer; 2012 Feb; 12(1):19-29. PubMed ID: 21903480
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bevacizumab for the first-line treatment of human epidermal growth factor receptor 2-negative advanced breast cancer.
    Damasceno M
    Curr Opin Oncol; 2011 Apr; 23 Suppl():S3-9. PubMed ID: 21490481
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evolving strategies for overcoming resistance to HER2-directed therapy: targeting the PI3K/Akt/mTOR pathway.
    Nahta R; O'Regan RM
    Clin Breast Cancer; 2010 Nov; 10 Suppl 3():S72-8. PubMed ID: 21115425
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeted Therapies in HER2-Positive Breast Cancer - a Systematic Review.
    Schramm A; De Gregorio N; Widschwendter P; Fink V; Huober J
    Breast Care (Basel); 2015 Jul; 10(3):173-8. PubMed ID: 26557822
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HER2-directed therapy for metastatic breast cancer.
    Jelovac D; Emens LA
    Oncology (Williston Park); 2013 Mar; 27(3):166-75. PubMed ID: 23687784
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Emerging drugs targeting human epidermal growth factor receptor 2 (HER2) in the treatment of breast cancer.
    Awada G; Gombos A; Aftimos P; Awada A
    Expert Opin Emerg Drugs; 2016; 21(1):91-101. PubMed ID: 26817602
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current and emerging targeted therapies for metastatic breast cancer.
    Perez EA; Spano JP
    Cancer; 2012 Jun; 118(12):3014-25. PubMed ID: 22006669
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of HER2 mutations in refractory metastatic breast cancers: targeted sequencing results in patients with refractory breast cancer.
    Park YH; Shin HT; Jung HH; Choi YL; Ahn T; Park K; Lee A; Do IG; Kim JY; Ahn JS; Park WY; Im YH
    Oncotarget; 2015 Oct; 6(31):32027-38. PubMed ID: 26397225
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pertuzumab in HER2-positive breast cancer.
    Sendur MA; Aksoy S; Altundag K
    Curr Med Res Opin; 2012 Oct; 28(10):1709-16. PubMed ID: 22953713
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term outcomes of neoadjuvant treatment of HER2-positive breast cancer.
    Zhang B; Hurvitz S
    Clin Adv Hematol Oncol; 2016 Jul; 14(7):520-30. PubMed ID: 27379947
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The emerging role of CDK4/6i in HER2-positive breast cancer.
    O'Sullivan CC; Suman VJ; Goetz MP
    Ther Adv Med Oncol; 2019; 11():1758835919887665. PubMed ID: 31832106
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiotoxicity of novel HER2-targeted therapies.
    Sendur MA; Aksoy S; Altundag K
    Curr Med Res Opin; 2013 Aug; 29(8):1015-24. PubMed ID: 23692263
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.